Bioventus Inc. Class A Common Stock (BVS) — Analysis Summary
Bioventus Inc. Class A Common Stock (BVS) has a market cap of $892.24M with year-over-year revenue growth of -0.9%. Net margin stands at 4.0%. The stock trades at a P/E ratio of 31.3.
Key Takeaways
- Revenue changed -0.9% year-over-year
- Net margin of 4.0%
- P/E ratio of 31.3
Compared to other companies in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector, BVS posted revenue growth of -0.9% and trades at a P/E of 31.3.
Bioventus Inc. Class A Common Stock (BVS)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsNo Major Flags
No major credit, margin, or trend red flags were triggered from the latest filings.
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Employees
940
Headquarters
DURHAM, NC
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
N/A
Dividend Yield
N/A
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.